Mobile

Study to determine whether ixazomib as maintenance therapy has an effect on progression free survival and compared to placebo in patients with newly diagnosed multiple myeloma who have not been treate...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001394-13

Study to determine whether ixazomib as maintenance therapy has an effect on progression free survival and compared to placebo in patients with newly diagnosed multiple myeloma who have not been treated with stem-cell transplantation

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the effect of ixazomib maintenance therapy on progression-free survival (PFS), defined as the time from randomization to progressive disease (PD) or death from any cause, compared with placebo, in patients with NDMM who have had a major response - defined as complete response (CR), very good partial response (VGPR), or partial response (PR) - to initial therapy and who have not undergone SCT

Critère d'inclusion

  • Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Liens